Thai male or female patients aged between 20-40 years with mild to severe acne vulgaris, classified as IGA grade 2-4. Acne vulgaris, 1726 nm laser, sebaceous gland, sebum production, C. acnes, porphyrin fluorescence, non-invasive treatment, acne treatment
Conditions
Interventions
Participants will receive treatment with an FDA approved 1726 nm laser to facial areas. Each participant will undergo a total of four treatment sessions at approximately four week intervals. Treatment
Experimental Device
Sponsors
Quanta System Asia Pacific
Eligibility
Sex/Gender
All
Age
20 Years to 40 Years
Inclusion criteria
Inclusion criteria: 1. Thai male or female patients aged between 20-40 years. 2. Diagnosis of mild to severe acne vulgaris, classified as IGA grade 2-4. 3. Willingness to comply with the study protocol, including attending follow-up visits, and provision of signed informed consent.
Exclusion criteria
Exclusion criteria: 1. Pregnancy or breastfeeding. 2. Use of systemic retinoid within the past 6 months. 3. Use of oral antibiotics or oral corticosteroids within 1 month prior to the study 4. Use of oral therapies affecting facial sebum production (e.g., oral contraceptives, or spironolactone) within 1 month prior to the study. 5. Use of topical acne medications (e.g., retinoid, antibiotics, benzyl peroxide, and corticosteroids) within 2 weeks prior to the study. 6. Use of laser resurfacing, chemical peeling, or dermabrasion within the past 1 month. 7. Use of botulinum toxin, dermal filler, or any cosmetic facial procedure within 6 months prior to the study. 8. Presence of other active skin lesions on the face (e.g., seborrheic dermatitis, atopic dermatitis, or eczema) 9. History of keloid formation or hypertrophic scarring. 10. Known allergy or sensitivity to any materials used during treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Acne lesion counts at baseline, during each treatment session, and at subsequent follow-up visits (at 1, 3, 6 months after final session) Acne lesion counts | — |
Secondary
| Measure | Time frame |
|---|---|
| Sebum production level At baseline, during each treatment session, and at subsequent follow-up visits (at 1, 3, 6 months after final session) Sebumeter,Acne severity At baseline, during each treatment session, and at subsequent follow-up visits (at 1, 3, 6 months after final session) Investigator Global Assessment (IGA) Scale,C. acne level At baseline, during each treatment session, and at subsequent follow-up visits (at 1, 3, 6 months after final session) Porphyrin fluorescence using the Trica 3D Skin Analysis System,Patients' pain score Immediately after each treatment session Visual Analogue Scale (VAS),Patient satisfaction scores Throughout the treatment period and at each follow-up visit Five-point scale ranging from -2 to 2,Adverse effects At the end of each treatment session and throughout the study Incidence of adverse effects | — |
Countries
Thailand
Contacts
Public ContactNichakul Kharuhayothin
Chulabhorn International College of Medicine, Thammasat University
Outcome results
None listed